Oramed Pharmaceuticals Reports Positive Results From A Study Of Oral Insulin Capsule On Type 1 Diabetic Patients
Oramed Pharmaceuticals Reports Positive Results From A Study Of Oral Insulin Capsule On Type 1 Diabetic Patients
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study marks Oramed's first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed's trials up to date have been conducted on type 2 diabetic patients.